STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.

◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.

◆ To complement the organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.

◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include National Institutes for Food and Drug Control, local Institutes for Drug Control and listed companies etc.
Abstract

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma volume and further intensified the tight supply of raw material plasma. But when it comes to the lot release volume, the blood product output in China grew as high as 15.4% YoY in 2011, and the market size rose 22% YoY to around RMB11.6 billion. Additionally, in consideration of 12th Five-Year Plan for Doubling Blood Product Supply proposed by the Minister of the Ministry of Health at the end of 2011, the issuance of Notice of the Ministry of Health on Management of Plasma Collection Stations in early 2012, and the domestic market demand & supply, the blood product market size in China is expected to maintain a high growth rate of over 20% in the five years to come.

However, the low degree of industry concentration, the companies’ weak R&D capabilities, short supply of raw material plasma and low plasma utilization rate affect the development of Chinese blood product industry to some extent. The blood products released in overseas market divide into around 40 varieties, and the international blood product giants can extract about 15 varieties of blood products from plasma, while among Chinese companies, Beijing Tiantan Biological Products Co., Ltd. can produce at most 11 varieties from plasma. Moreover, Chinese blood product market is principally concentrated on human albumin and human immunoglobulin (pH4) for intravenous injection which pose low requirements on technologies. In 2011, the lot release volume of the two products made up 53.4% and 16.8% of the total release volume respectively.
Blood coagulation factor and thrombin products feature the largest demand gap in China, but there are less domestic supply and fewer producers. In 2011, the manufacturers of Human Coagulation Factor VIII in China just include Shanghai RAAS Blood Products, Green Cross China and Hualan Biological Engineering Inc., with lot release volume adding up to 350,000 bottles, and the producers of Human Prothrombin Complex are Hualan Biological Engineering Inc., Shanghai RAAS Blood Products and Shanghai Xinxing Medicine, with lot release volume totaling 200,000 bottles. Essentially, subsidiaries under China National Biotech Group and other Groups that possess production capacity and obtain governmental approvals in Coagulation Factor VIII and IX do not conduct production in recent years. With the intensifying contradiction between supply and demand, the government may launch intervention measures to enable the enterprises with the approval to restart the manufacturing of these products to raise overall supply of products of this sort.
Although taking such factors like home market demand into account, China has allowed the import of some blood products, but the imports are confined to human albumin and recombinant coagulation factor. Moreover, blood product manufacturing is a sector with no allowance for foreign capital. The imported human albumin almost makes up 50% market share, and the proportion reached 43.3% in 2011.

Following the tougher conflict between supply & demand and the loosening of policies in China, foreign brands quicken their pace of tapping into Chinese market. In May 2012, SFDA approved the release of Baxter’s ADVATE (Recombinant Human Coagulation Factor VIII for injection) in China which was another foreign brand of coagulation factor after the imported Bayer’s Recombinant Coagulation Factor VIII in 2007. Moreover, Pfizer is applying for quick approval program for its Recombinant Coagulation Factor IX (obtained from Wyeth).

The report resolves around the followings:

◆ The plasma volume, distribution of plasma stations, market size and supply & demand of Chinese blood product industry;

◆ Competition pattern, policy climate and import & export of Chinese blood product industry;

◆ Market supply & demand and competitive landscape of 8 blood products such as human albumin, human immunoglobulin (pH4) for intravenous injection and coagulation factor, etc.

◆ Status quo, operation, plasma collection station and product lot release volume of 9 Chinese blood product manufacturers.
## 1. Profile of Blood Products

1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

## 2. Overview of China Blood Products Industry

2.1 Market Size
2.2 Development Status
2.3 Market Supply & Demand
2.3.1 Supply
2.3.2 Demand
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

## 3. Blood Product Market Segments in China

3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.3 Coagulation Factor
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.5 Human Immunoglobulin
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Supply & Demand
3.8.2 Competition Pattern

## 4. Key Manufacturers in China

4.1 Hualan Biological Engineering Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Clients and Suppliers
4.1.6 R&D and Investment
4.2 Shanghai RAAS Blood Products Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R&D and Investment
4.3 Beijing Tiantan Biological Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 Blood Products
4.4 China Biologic Products Inc.
4.5 Jiangxi Boya Biopharmaceutical Co., Ltd.
4.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7 CNBG Shanghai Institute of Biological Products
4.8 Shanxi Kangbao Biological Product Co., Ltd.
4.9 Green Cross
• Basic Components of Blood
• Classification and Effects of Blood Products
• Comparison between Gene Recombinant Blood Products and Traditional Blood Products
• Categories and Comparison of Recombinant Blood Products in China and Worldwide
• Blood Product Industry Chain
• Lot Release Volume of Blood Products (by Product) in China, 2007-2011
• Product Structure of Blood Products in China (by Lot Release Volume), 2009-2011
• Annual Plasma Volume in China, 2002-2011
• Geographical Distribution of Plasma Collection Station Resources in China, by the End of 2011
• Medical Insurance Coverage in Mainstream Blood Products in China
• Comparison of Per Capita Usage of Blood Products between China and Developed Countries
• Comparison among Blood Product Manufacturing Enterprises in China by Product Line
• Blood Products in Overseas Countries
• On-going Clinical Trial of New Indications Overseas
• Global Blood Products Manufacturers
• Major Policies Concerning Blood Products in China
• Sales Value and Total Profit of Biological & Biochemical Product Industry in China, 2008-2011
• Ratio of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2010
• Market Share of Major Manufacturers of Human Albumin in China (by Lot Release Volume), 2007-2011
• Comparison between China and USA by Consumption of Human Immunoglobulin (pH4) for Intravenous Injection, 2010
• Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2010
• Prices of Human Immunoglobulin (pH4) for Intravenous Injection in China and Other Countries
Selected Charts

- Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2011
- Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2011
- Market Share of Major Manufacturers of Coagulation Factor VIII in China (by Lot Release Volume), 2008-2011
- Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII
- Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2011
- Market Share of Major Manufacturers of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2008-2011
- Lot Release Volume and Its Growth Rate of Human Immunoglobulin in China, 2008-2011
- Market Share of Major Manufacturers of Human Immunoglobulin in China (by Lot Release Volume), 2008-2011
- Lot Release Volume and Its Growth Rate of Human Prothrombin Complex in China, 2008-2011
- Market Share of Manufacturers of Human Prothrombin Complex in China (by Release Volume), 2008-2011
- Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in China, 2008-2011
- Market Share of Major Manufacturers of Tetanus Immunoglobulin in China (by Release Volume), 2008-2011
- Lot Release Volume and Its Growth Rate of Human Rabies Immunoglobulin in China, 2008-2011
- Market Share of Major Manufacturers of Human Rabies Immunoglobulin in China (by Release Volume), 2008-2011
- Revenue and Total Profit of Hualan Biological, 2007-2012
- Revenue Breakdown of Hualan Biological by Industry, 2007-2011
- Revenue Structure of Hualan Biological by Industry, 2007-2011
- Revenue Breakdown of Hualan Biological by Product, 2007-2011
- Revenue Structure of Hualan Biological by Product, 2007-2011
- Revenue Breakdown of Hualan Biological by Region, 2007-2011
- Revenue Structure of Hualan Biological by Region, 2007-2011
- Gross Margin of Hualan Biological by Industry, 2007-2011
- Gross Margin of Hualan Biological by Product, 2007-2011
- Hualan Biological's Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
• Hualan Biological's Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011
• R&D Costs and % of Total Revenue of Hualan Biological, 2007-2011
• Distribution of Plasma Collection Stations of Hualan Biological, 2011
• Lot Release Volume of Blood Products of Hualan Biological, 2008-2011
• Proportion of Blood Products Release Volume of Hualan Biological, 2008-2011
• Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2011
• Revenue and Gross Margin of Blood Products of Hualan Biological (by Product), 2007-2011
• Distribution of Plasma Collection Stations of Shanghai RAAS Blood Products Co., Ltd, by the End of 2011
• Revenue and Profit of Shanghai RAAS, 2007-2012
• Lot Release Volume of Blood Products of Shanghai RAAS Blood Products Co., Ltd, 2007-2011
• Proportion of Blood Products Release Volume of Shanghai RAAS, 2007-2011
• Revenue Breakdown of Shanghai RAAS by Product, 2007-2011
• Revenue Structure of Shanghai RAAS by Product, 2007-2011
• Revenue Breakdown of Shanghai RAAS by Region, 2007-2011
• Revenue Structure of Shanghai RAAS by Region, 2007-2011
• Gross Margin of Shanghai RAAS by Product, 2007-2011
• Shanghai RAAS’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
• Name List and Revenue Contribution of Shanghai RAAS’s Top 5 Clients, 2011
• Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011
• R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2011
• Revenue and Net Income of Tiantan Biological’s Major Joint-stock Companies, 2011
• Revenue and Total Profit of Beijing Tiantan Biological, 2007-2012
• Revenue Breakdown of Beijing Tiantan Biological by Industry, 2007-2011
• Revenue Breakdown of Beijing Tiantan Biological by Region, 2007-2011
• Gross Margin of Beijing Tiantan Biological by Industry, 2007-2011
• Gross Margin of Beijing Tiantan Biological by Region, 2007-2011
• Beijing Tiantan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011
• Beijing Tiantan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
• Name List and Revenue Contribution of Top 5 Clients of Beijing Tiantan Biological’s Top 5 Clients, 2011
• Distribution of Plasma Collection Stations of Beijing Tiantan Biological, by the End of 2011
• Revenue and Gross Margin of Blood Products of Beijing Tiantan Biological, 2007-2011
• Lot Release Volume of Blood Products of Chengdu Rongsheng, 2007-2011
• Equity Structure of China Biologic Product Inc.
• Revenue and Operating Income of China Biologic Products Inc., 2007-2011
• Revenue Structure of China Biologic Products Inc. by Product, 2008-2011
• Plasma Collection Costs of China Biologic Products Inc., 2008-2011
• China Biologic Products Inc.’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
• Name List and Revenue Contribution of China Biologic Products Inc.’s Top 5 Clients, 2011
• Name List and Procurement Contribution of China Biologic Products Inc.’s Top 10 Suppliers, 2011
• Lot Release Volume of Blood Products of Shandong Taibang, 2007-2011
• Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011
• Lot Release Volume of Blood Products of Xi’an Hui Tian, 2007-2011
• Plasma Inventory, Plasma Collection Amount and Plasma Volume of Boya Biopharmaceutical, 2009-2011
• Distribution and Collection Amount of Plasma Collection Stations of Boya Biopharmaceutical, 2009-2011
• Revenue and Profit of Boya Biopharmaceutical, 2009-2012
• Revenue Breakdown of Boya Biopharmaceutical by Product, 2009-2011
• Revenue Structure of Boya Biopharmaceutical by Product, 2009-2011
• Lot Release Volume of Blood Products of Boya Biopharmaceutical, 2007-2011
• Revenue Breakdown of Boya Biopharmaceutical by Region, 2009-2011
• Revenue Structure of Boya Biopharmaceutical by Region, 2009-2011
• Gross Margin of Boya Biopharmaceutical by Product, 2009-2011
• Boya Biopharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
• Name List and Revenue Contribution of Boya Biopharmaceutical’s Top 5 Clients, 2011
• Boya Biopharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
• Name List and Procurement Contribution of Boya Biopharmaceutical’s Top 5 Suppliers, 2011
• Output & Sales Volume and Inventory of Boya Biopharmaceutical by Product, 2009-2011
• Prices of Boya Biopharmaceutical by Product, 2009-2011
• R&D Costs and % of Total Revenue of Boya Biopharmaceutical, 2009-2011
• Blood Product R&D Projects and Progress of Boya Biopharmaceutical, by the End of 2011
• Distribution of Plasma Collection Stations of Yuanda Shuyang, by the End of 2011
• Lot Release Volume of Blood Products of Yuanda Shuyang, 2007-2011
• Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-2011
• Distribution of Plasma Collection Stations of CNBG Shanghai Institute of Biological Products, by the End of 2011
• Distribution of Plasma Collection Stations of Shanxi Kangbao, by the End of 2011
• Lot Release Volume of Blood Products of Shanxi Kangbao, 2007-2011
• Distribution of Plasma Collection Stations of Green Cross, by the End of 2011
• Lot Release Volume of Blood Products of Green Cross, 2007-2011
You can place your order in the following alternative ways:

1. Order online at [www.researchinchina.com](http://www.researchinchina.com)
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828 / 82601561

<table>
<thead>
<tr>
<th>Party A:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Person:</td>
<td>Tel</td>
<td></td>
</tr>
<tr>
<td>E-mail:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Party B:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
<td>Beijing Waterwood Technologies Co., Ltd (ResearchInChina)</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080</td>
<td></td>
</tr>
<tr>
<td>Contact Person:</td>
<td>Liao Yan</td>
<td>Phone: 86-10-82600828</td>
</tr>
<tr>
<td>E-mail:</td>
<td><a href="mailto:report@researchinchina.com">report@researchinchina.com</a></td>
<td>Fax: 86-10-82601570</td>
</tr>
</tbody>
</table>

| Bank details: | Beneficial Name: Beijing Waterwood Technologies Co., Ltd |            |
| Bank Name: | Bank of Communications, Beijing Branch |            |
| Bank Address: | NO.1 jinxiyuan shijcheng, Landianchang, Haidian District, Beijing |            |
| Bank Account No #: | 110060668012015061217 |            |
| Routing No #: | 332906 |            |
| Bank SWIFT Code: | COMMCCNSBJG |            |

<table>
<thead>
<tr>
<th>Title</th>
<th>Format</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard copy</td>
<td></td>
<td>2,400 USD</td>
</tr>
<tr>
<td>PDF (Single user license)</td>
<td></td>
<td>2,300 USD</td>
</tr>
<tr>
<td>PDF (Enterprisewide license)</td>
<td></td>
<td>3,600 USD</td>
</tr>
</tbody>
</table>

※ Reports will be dispatched immediately once full payment has been received.

Payment may be made by wire transfer or credit card via PayPal.